Form 8-K - Current report:
SEC Accession No. 0001193125-22-054425
Filing Date
2022-02-25
Accepted
2022-02-25 16:15:14
Documents
13
Period of Report
2022-02-18
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d275375d8k.htm   iXBRL 8-K 25707
  Complete submission text file 0001193125-22-054425.txt   190990

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA crxt-20220218.xsd EX-101.SCH 4481
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE crxt-20220218_def.xml EX-101.DEF 14243
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE crxt-20220218_lab.xml EX-101.LAB 23884
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE crxt-20220218_pre.xml EX-101.PRE 15270
7 EXTRACTED XBRL INSTANCE DOCUMENT d275375d8k_htm.xml XML 5823
Mailing Address 555 SKOKIE BOULEVARD, SUITE 340 NORTHBROOK IL 60062
Business Address 555 SKOKIE BOULEVARD, SUITE 340 NORTHBROOK IL 60062 (847) 562-4300
Clarus Therapeutics Holdings, Inc. (Filer) CIK: 0001817944 (see all company filings)

IRS No.: 851231852 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39802 | Film No.: 22680147
SIC: 2836 Biological Products, (No Diagnostic Substances)